Market Trends of Ligases Enzyme Industry
This section covers the major market trends shaping the Ligases Enzyme Market according to our research experts:
Polymerase Chain Reaction Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period
Polymerase Chain Reaction (PCR) is expected to dominate the ligases enzyme market through the forecast period. PCR involves a thermostable ligase to join two probes or other molecules together. The increasing prevalence of cancer is expected to contribute to the growth of the studied segment owing to potential therapeutic interventional benefits.
As per the data from the ACS report published in 2022, it is observed that there will be around 1.91 million new cancer cases in the United States in 2022. Among the cancer cases, cancers of the genital and digestive systems were expected to be the highest, with 395,600 and 343,040 new cases, respectively. Such a high incidence of cancer is expected to drive the demand for effective therapeutics, thereby driving the growth of the ligase enzymes market owing to its potential therapeutic interventional properties.
The increasing funding from government and market players' strategies, such as collaborations and partnerships, are expected to fuel the growth of the studied segment. For instance, in May 2021, QIAGEN NV announced a global partnership with Mirati Therapeutics Inc. to advance the development of a tissue-based KRAS companion diagnostic to detect individuals with malignancies that carry the KRASG12C mutation. The intended companion diagnosis would add to QIAGEN's therascreen KRAS testing lineup for the Rotor-Gene Q MDx instrument, which is based on real-time qualitative PCR. Additionally, the Indian Finance Minister suggested allocating Rs 2.23 lakh crore (USD 2699.9 million) for health and wellbeing in the Union Budget 2021-22. This represents a 137% increase over projected expenditure for healthcare in the 2021 fiscal, and it will significantly alter the Indian healthcare system, particularly through the improvement and modernization of the current diagnostic equipment, such as PCR, in government hospitals.
North America is Expected to Hold Significant Share in the Market During the Forecast Period
North America is a prominent market due to the well-established end-user industries, such as molecular biology laboratories, research institutes, and pharmaceutical companies.
Factors such as the increasing prevalence of various infectious diseases among the North American population drive the demand for effective diagnostics and therapeutics, thereby expected to drive the growth of the market. For instance, as per the CDC data in March 2022, tuberculosis incidence increased by 9.4% from 2020 to 2021 in the United States. Also, the article published by VDH in 2022 mentioned that the incidence rate of tuberculosis in Mexico was nearly 20 per 100,000 persons annually. Additionally, the report published by Tand F Journal in March 2022 mentioned that the incidence rate of tuberculosis among the Canadian population was 4.7 per 100,000 persons annually. Such high incidences of infectious diseases are expected to drive the demand for ligases enzyme, thereby contributing to the market's growth over the forecast period.
Moreover, the increasing market players' activities, such as partnerships, collaborations, and others, are expected to fuel the market growth in this region. For instance, in October 2022, Takara Bio partnered with BioExcel Diagnostics to develop and validate a new throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time PCR automation technology and reagents such as ligases from Takara Bio.
Thus, the high prevalence of infectious diseases, rising market player activities, and the presence of key market players are expected to drive the growth of the market in this region.